scispace - formally typeset
S

Shiran Shapira

Researcher at Tel Aviv Sourasky Medical Center

Publications -  58
Citations -  611

Shiran Shapira is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 47 publications receiving 449 citations. Previous affiliations of Shiran Shapira include Tel Aviv University.

Papers
More filters
Journal ArticleDOI

Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer.

TL;DR: It is reported that eosinophils are recruited into developing tumors during induction of inflammation-induced colorectal cancer and in mice with the Apcmin/+ genotype, which develop spontaneous intestinal adenomas, and it is demonstrated that the TME supported prolonged eos inophil survival independent of IL5, an eosInophils survival cytokine.
Journal ArticleDOI

Recent advances in personalized colorectal cancer research

TL;DR: Currently known molecular biomarkers used for the personalized treatment of colorectal cancer are reviewed to identify reliable biomarkers which will guide clinicians in decision making, while matching suitable therapeutic regimens.
Journal ArticleDOI

Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers.

TL;DR: The possible molecular mechanism for terpinen-4-ol activity involves induction of cell-death rendering this compound as a potential anti-cancer drug alone and in combination in the treatment of numerous malignancies.
Journal ArticleDOI

An Immunoconjugate of Anti-CD24 and Pseudomonas Exotoxin Selectively Kills Human Colorectal Tumors in Mice

TL;DR: Anti-CD24 SWA11 mAb can deliver a PE exotoxin derivative to CRC cells and cause them to undergo apoptosis, without toxicity to normal tissues.
Journal ArticleDOI

The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews.

TL;DR: The APC p.I1307K gene variant is an important risk factor for colorectal neoplasia in average risk Ashkenazi Jews, and carriers in this group should be considered for screening colonoscopy at the age of 40, to be repeated every 5 years, similar to recommendations in individuals with family history of coloreCTal cancer.